Articles tagged with Cancer Medication
Researchers from Mount Sinai presented several landmark studies on late-stage cancer treatment trends, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate, and bladder cancer. The studies aimed to identify factors associated with lack of treatment and explore new treatments for various cancers.
A study published in Science Translational Medicine found that daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30%, compared to those not taking daclizumab. The drug depletes regulatory T cells, allowing immune cells to fight tumors more effectively.
A phase 1 clinical trial of the drug crizotinib achieved remissions with minimal side effects for 10 children with lymphoma and neuroblastoma. The study showed great potential for targeted therapy in children with anaplastic large cell lymphoma, with some patients achieving complete responses.
Researchers have discovered a combination of lapatinib and cetuximab to be effective against cancers that have developed resistance to traditional therapies. In the clinical trial, two out of nine patients showed a partial response to the treatment.
A phase II clinical trial found that abiraterone acetate, a hormone-depleting drug, can nearly eliminate or eliminate tumors in patients with aggressive cancers isolated to the prostate gland. The study showed promising results, encouraging further research into new treatments for high-risk prostate cancer.
A collaborative study is exploring the proteome of triple negative breast cancers to identify new drug therapies and diagnostic tools. The researchers aim to understand how cancer cells operate and find proteins that could suggest treatment options.
Researchers have developed a new series of drugs that target the fox tapeworm, which causes rare but life-threatening disease in humans. The drugs, derived from anti-cancer agents, show potential in killing the parasite and treating the disease.
The American Society of Clinical Oncology (ASCO) has released five new studies at its upcoming annual meeting, including those on precision medicine and cancer's genetic weak spots. These studies demonstrate improvements in treatment for aggressive cancers and provide valuable tools to lessen the side effects of cancer treatment.
High doses of beta-carotene, selenium, and folic acid have been shown to increase cancer risk in a recent study. The University of Colorado Anschutz Medical Campus has warned that these supplements should not be taken beyond their recommended daily allowance.
A new biomarker, PEAK1, has been identified for pancreatic cancer, a disease with low survival rates. Inhibition of PEAK1-dependent signaling sensitizes PDAC cells to existing chemotherapies.
A cancer vaccine targeting MUC1 glycoprotein significantly increased survival when combined with the drug letrozole in mice. The findings suggest a promising new approach to combating cancer using immunotherapy.
Researchers found that administering cyclophosphamide before bone tumors took root fertilized the bone marrow, enabling cancer cells to seed and grow. The study reversed this effect by inhibiting CCL2, suggesting a potential approach for preventing metastasis in certain cancers.
A new study describes a compound that selectively kills cancer cells by restoring the structure and function of mutant p53. This finding supports the development of rationally targeted cancer therapies and has potential for treating 30,000 patients annually in the US.
Researchers found no link between beta blocker use and colorectal cancer risk, even after considering patient characteristics. Long-term use or subtypes of beta blockers showed no reduction in colorectal cancer risk.
Scientists at UTHealth Medical School have made a key discovery in cell signaling relevant to the fight against melanoma skin cancer. They found that BRaf inhibitors, widely used to treat melanomas, can actually enhance abnormal signaling activity when applied to cells with Ras mutations.
Researchers at the University of Pittsburgh Cancer Institute have identified a molecule activated by a virus that can selectively kill tumor cells in animal studies. A new drug candidate, YM155, has shown promising results in killing MCC cells and suppressing tumor growth.
Researchers at IBN developed a miniaturized biochip, Droplet Array, to study the effect of drugs on cancer stem cells (CSCs). The new technology shows CSCs can survive chemotherapy and drive metastasis, highlighting the need for more effective cancer drugs.
Researchers have developed a potent new drug called Lys05 that kills tumor cells in mouse models by clogging their recycling system. This approach has shown promise as a single-agent anti-tumor therapy with minimal toxicity to healthy cells.
A new study launched by University of Leicester is exploring whether tablets containing curcumin can enhance the effectiveness of chemotherapy for advanced bowel cancer. The trial aims to recruit 40 patients and investigate the safety and efficacy of adding curcumin to standard treatment.
Researchers at Washington University School of Medicine identified a cancer drug, idarubicin, that enhances the human body's innate antiviral system. The new strategy screens large numbers of existing drugs to find compounds that activate genes boosting natural immunity.
A $4.5 million grant will fund the search to find new ways of treating glioblastoma multiforme (GBM), the most common type of primary brain tumors. The study aims to discover new medicines that can precisely target tumors, shrinking or eliminating them with minimal harm.
Researchers at the University of Georgia found that long-term lack of oxygen in cells may be a key driver of cancer growth. Cancer cells switch to glycolysis for energy production, leading to a vicious cycle of increased hunger and growth.
A new analysis by French researchers identified patients with low phosphatidylinositol 3-kinases (PI3K) levels and low expression of the protein LKB1 as likely to benefit from everolimus treatment in breast cancer, contradicting initial hypotheses.
Researchers at IDIBELL discovered that combining two mTOR inhibitors can stop liver cancer growth and destroy tumor cells. A clinical trial is underway to evaluate the efficacy of this combination in humans.
A UNC study successfully delivers therapeutic doses of a cancer drug using nanoparticle carriers, overcoming pharmacologic challenges that led to its abandonment. The study demonstrates improved efficacy and reduced toxicity for the abandoned drug.
A landmark study found that bevacizumab (Avastin) is equivalent to ranibizumab (Lucentis) in treating wet age-related macular degeneration through two years, with monthly dosing producing slightly more vision gain. The study showed similar visual results regardless of dosing frequency, with 60% of patients achieving driving vision.
A new study found that only 6% of breast cancer survivors experience persistent and debilitating fatigue a year after treatment, contradicting previous reports. The researchers suggest that factors unrelated to the cancer or its treatment may have contributed to the high rates of reported fatigue.
The Journal of the National Cancer Institute warns that dietary supplements may lower cancer risk, but only observational studies support this claim. Randomized controlled trials show no correlation between supplement use and reduced cancer risk.
The Domino technology, developed at the University of Alberta, enables fast and accurate genetic testing using a miniaturized plastic chip. The innovation has the potential to transform point-of-care medicine, making it possible to screen large populations in a short time.
A new study published in PLoS ONE found that anxious mice developed more severe cancer than calm counterparts, with accelerated tumor growth and invasive cancer. The researchers discovered that anxiety is linked to increased levels of immune-suppressing cells and a dampened immune system.
Researchers from IMIM and UPF identified 115 proteins in silico that could be highly relevant to treat colon-rectal cancer, enabling the design of new generation anti-cancer drugs. The study uses a computational method to predict proteins that interact with molecules showing differential cytotoxicity.
Researchers at Vetmeduni Vienna have shown that chronic myeloid leukaemia (CML) and B-cell acute lymphoid leukaemia (B-ALL) arise from the same long-term haematopoietic stem cells. Understanding this finding is crucial for developing targeted therapies, as current treatments may not effectively target cancer stem cells.
A recent shortage of prescription generic drugs in Canada has highlighted the issue for two years, with up to 98% of pharmacists experiencing shortages during working shifts. The problem is exacerbated by the affordability issues faced by 10% of Canadians who rely on these medications.
Researchers at the University of Warwick discovered the precise mechanism by which spindle checkpoint proteins bind chromosomes. This breakthrough understanding could lead to the development of more selective and effective cancer drugs, potentially reducing debilitating side effects.
Researchers have reclassified breast cancer into 10 subtypes based on genetic features, allowing doctors to predict tumor behavior and tailor treatment. The study also discovered several completely new genes linked to breast cancer, which could lead to the development of new drugs and treatments.
The Clinical Research Forum announced Top 10 Clinical Research Achievement Awards for outstanding projects tackling difficult health problems, including disease prevention, cystic fibrosis, leukemia, and cardiovascular disease. The top prize was awarded for HIV transmission prevention through early treatment.
Scientists are developing new medicines based on epigenetics, a quiet revolution in biology and chemistry that influences how genes work in health and disease. Four drugs approved for blood cancer have limitations due to lack of selectivity.
Researchers at Case Western Reserve University have developed a magnetic nanochain delivery system that explodes chemotherapy drugs inside tumors, killing cancer cells more efficiently. The technology reduced tumor growth by up to 90% and increased survival rates in rats with triple-negative breast cancer.
Researchers used live microscopy to observe how cancer cells react to chemotherapy in different tumor microenvironments. Selective inhibition of certain enzymes and immune signaling molecules made breast tumors more responsive to doxorubicin, a widely used chemotherapeutic agent.
A new study finds that immunotherapy can be effective in elderly cancer patients when combined with a specific treatment targeting age-related immune suppressor cells. The approach offers less toxic effects and improved outcomes compared to traditional therapies.
Researchers have discovered that activating mutations in the FLT3 gene play a crucial role in acute myeloid leukemia, making it an attractive target for new treatments. The study identifies drug-resistant mutations in FLT3 and suggests that therapies involving combinations of multiple drugs could suppress these mutated forms.
A web-based intervention tool called Guide to Decide helped post-menopausal women understand their breast cancer options and feel comfortable with their choice, leading to less uncertainty and increased decision-making. The study found that tailored information reduced anxiety and improved decision outcomes for high-risk women.
A University of Miami study shows that physically active women with non-metastatic breast cancer experience reduced depression and fatigue, as well as improved quality of life. Women who engaged in regular physical activity reported less debilitating fatigue and an enhanced ability to perform daily activities.
Researchers at Case Western Reserve University identified a set of master switches, called Variant Enhancer Loci (VELs), that regulate key genes in colon cancer. VELs are epigenetic changes that can potentially be reversed and may play a role in determining individual susceptibility to colon cancer.
A study by Michigan Oncology Quality Consortium found that most practices followed guidelines for breast, colorectal, and lung cancers, but had gaps in managing symptoms and end-of-life care. To improve quality, the consortium initiated a project to provide palliative care delivery.
Researchers develop new methods for injecting drugs and genetic payloads directly into cancer cells using plasmonic nanobubbles. Delivering chemotherapy with nanobubbles increases efficacy and reduces dosage, targeting single-cell level cancer treatment.
A new report by American Cancer Society scientists reveals that daily low-dose aspirin use may lower overall cancer incidence and mortality. The study found a significant reduction in cancer death, even at doses as low as 75 mg daily.
Researchers identified hundreds of novel genes mutated in stomach cancer, which could lead to targeted therapies. FAT4 and ARID1A were found to be particularly interesting, with mutations detected in 5% and 8% of stomach cancers, respectively.
Northwestern University scientists develop gold nanostars that target cancer cells' nucleus, releasing a killing drug. The nanoparticles are attracted by a protein on the surface and change shape after drug release, causing cell death.
A McGill University team has developed a new microarray technology that can accurately measure multiple proteins in a droplet of blood to detect breast cancer. The test, which uses a 'fingerprint' approach, showed promise in classifying patients with estrogen receptor-positive breast cancer.
BIND Biosciences presents late-breaker clinical data for BIND-014, a targeted docetaxel Accurin, showing anti-tumor activity in six of 17 patients with advanced or metastatic solid tumor cancers. The study demonstrated partial response or stable disease with durable responses of up to six months.
Researchers at Fox Chase Cancer Center have developed a new approach to overcome drug resistance in colorectal cancer patients. Their novel drug, ARI-4175, has shown promise in extending survival by enlisting the body's own immune system to reject tumors.
Researchers have successfully tested the first targeted cancer drug called BIND-014, demonstrating its ability to target receptors in tumors and achieve high tumor concentrations. The study shows remarkable efficacy, safety, and pharmacological properties compared to traditional chemotherapy.
A University of Colorado Cancer Center study found that men taking crizotinib for lung cancer experience a significant drop in testosterone levels, which can lead to fatigue, low bone density, and decreased sex drive. Regular monitoring and treatment of testosterone deficiency can improve patients' overall quality of life.
BIND-014, a novel Accurin nanoparticle, demonstrates high drug concentration in tumors and promising clinical effects in advanced or metastatic cancers. Preclinical data show up to ten-fold increase in intratumoral drug concentrations with prolonged tumor growth suppression.
A study by Dana-Farber Cancer Institute reveals that rapamycin triggers diabetic-like symptoms in some patients through activity of protein YY1. The researchers found that mice without the YY1 protein were protected against the effects, raising caution about the use of rapamycin.
A new drug developed by Northwestern Medicine scientists has prevented human prostate cancer cells from spreading to other tissues. The drug inhibits movement of the cells and prevents metastasis without causing harm to normal cells or tissues.
Rapamycin, a widely used cancer and transplant drug, leads to diabetes in 15% of patients due to its effect on muscle cells' insulin signal. Researchers discovered that a single transcription factor, YY1, plays a key role in this process. Mice lacking YY1 are protected from diabetes when taking rapamycin.
Researchers at Fox Chase Cancer Center have identified a new compound that targets a key pathway in lymphoma, suggesting it could be the first to hit this critical mechanism. The study found that certain types of lymphoma cells are more vulnerable to the effects of the compound, making them potential candidates for early clinical trials.
A harmless human virus, RT3D, has shown promise in boosting the effects of chemotherapy drugs in advanced head and neck cancer patients. In a Phase I/II trial, approximately one-third of patients experienced tumor shrinkage and disease stabilization.